Source: Health Products Regulatory Authority (ZA) Revision Year: 2024 Publisher: CIPLA MEDPRO MANUFACTURING (PTY) LTD., 1474 South Coast Road, Mobeni, Durban, 4052, Customer care: 080 222 6662
LOMIDA (50/300 mg film-coated tablets).
| Pharmaceutical Form |
|---|
|
Film-coated tablets. LOMIDA are grey coloured, capsule shaped, biconvex, film-coated tablets debossed with “C” on one side and plain on other side. |
Each film-coated tablet contains dolutegravir sodium equivalent to dolutegravir 50 mg and lamivudine 300 mg.
Contains sugar: mannitol 145,00 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. |
|
Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. |
| List of Excipients |
|---|
|
Colloidal silicon dioxide Contents of the film-coating (Opadry Gray): Ferrosoferric oxide/Black iron oxide |
LOMIDA is packed in a 50 cc white round high density polyethylene (HDPE) bottle with 33 mm blue child resistant cap. Pack sizes are 28’s and 30’s.
CIPLA MEDPRO MANUFACTURING (PTY) LTD., 1474 South Coast Road, Mobeni, Durban, 4052, Customer care: 080 222 6662
54/20.2.8/0642.641
25 May 2021
| Drug | Countries | |
|---|---|---|
| LOMIDA | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.